| Market Cap | $603.45M+78.2% |
| Revenue (ttm) | n/a |
| Net Income | -$46.26M |
| EPS | -$0.83 |
| Shares Out | 83.81M |
| PE Ratio | n/a |
| Forward PE | -7.12 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 993,758 |
| Open | $7.48 |
| Previous Close | $7.48 |
| Day's Range | $7.12 - $7.52 |
| 52-Week Range | $3.78 - $15.10 |
| Beta | 0.29 |
| Analysts | Strong Buy |
| Price Target | $23.93(+232.29%) |
| Earnings Date | Nov 12, 2026 |
About IMMX
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$IMMX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in IMMX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by IMMX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
IMMX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New IMMX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to IMMX from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from IMMX’s recent data — informational, not investment advice
What’s Behind the Score
News check: Bullish interim trial data and Q3 results offset by modest analyst price target reduction while maintaining outperform rating.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| BBC | Virtus Biotech Clinical Trials ETF | 0.76% |
| DWAS | Invesco Dorsey Wright SmallCap Momentum ETF | 0.53% |
| XBI | State Street SPDR S&P Biotech ETF | 0.17% |
| IWC | iShares Micro-Cap ETF | 0.13% |
| OPTZ | Optimize Strategy Index ETF | 0.11% |
| VFMO | Vanguard U.S. Momentum Factor ETF | 0.10% |
| TNXT | T. Rowe Price Innovation Leaders ETF | 0.06% |
| VMO.TO | Vanguard Global Momentum Factor ETF | 0.05% |
| VTWG | Vanguard Russell 2000 Growth ETF | 0.04% |
| PWS | Pacer WealthShield ETF | 0.04% |
| LABU | Direxion Daily S&P Biotech Bull 3X Shares | 0.03% |
| IWO | iShares Russell 2000 Growth ETF | 0.03% |
Weight is the stock’s share of each fund’s holdings.
